COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022

Limor Kliker; Neta Zuckerman; Nofar Atari; Noam Barda; Mayan Gilboa; Ital Nemet; Bayan Abd Elkader; Ilana S. Fratty; Hanaa Jaber; Ella Mendelson; Sharon Alroy-Preis; Yitshak Kreiss; Gili Regev-Yochay; Michal Mandelboim

doi:10.2807/1560-7917.ES.2022.27.30.2200559

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022

Limor Kliker
, Neta Zuckerman
, Nofar Atari
, Noam Barda
, Mayan Gilboa
, Ital Nemet
, Bayan Abd Elkader
, Ilana S. Fratty
, Hanaa Jaber
, Ella Mendelson
, Sharon Alroy-Preis
, Yitshak Kreiss
, Gili Regev-Yochay
, Michal Mandelboim

Ministry of Health, Israel
Tel Aviv University
Sheba Medical Center at Tel Hashomer

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

This work evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.4 and BA.5) in healthcare workers who had breakthrough BA.1 infection. Omicron breakthrough infection in individuals vaccinated three or four times before infection resulted in increased neutralising antibodies against the WT virus. The fourth vaccine dose did not further improve the neutralising efficiency over the third dose against all Omicron variants, especially BA.4 and BA.5. An Omicron-specific vaccine may be indicated.

Original language	English
Journal	Eurosurveillance
Volume	27
Issue number	30
DOIs	https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200559
State	Published - 28 Jul 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.2807/1560-7917.ES.2022.27.30.2200559

Cite this

Kliker, L., Zuckerman, N., Atari, N., Barda, N., Gilboa, M., Nemet, I., Elkader, B. A., Fratty, I. S., Jaber, H., Mendelson, E., Alroy-Preis, S., Kreiss, Y., Regev-Yochay, G., & Mandelboim, M. (2022). COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022. Eurosurveillance, 27(30). https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200559

@article{39669be180a24f95b16279c0b59d221e,

title = "COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022",

abstract = "This work evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.4 and BA.5) in healthcare workers who had breakthrough BA.1 infection. Omicron breakthrough infection in individuals vaccinated three or four times before infection resulted in increased neutralising antibodies against the WT virus. The fourth vaccine dose did not further improve the neutralising efficiency over the third dose against all Omicron variants, especially BA.4 and BA.5. An Omicron-specific vaccine may be indicated.",

author = "Limor Kliker and Neta Zuckerman and Nofar Atari and Noam Barda and Mayan Gilboa and Ital Nemet and Elkader, \{Bayan Abd\} and Fratty, \{Ilana S.\} and Hanaa Jaber and Ella Mendelson and Sharon Alroy-Preis and Yitshak Kreiss and Gili Regev-Yochay and Michal Mandelboim",

year = "2022",

month = jul,

day = "28",

doi = "10.2807/1560-7917.ES.2022.27.30.2200559",

language = "אנגלית",

volume = "27",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "30",

}

Kliker, L, Zuckerman, N, Atari, N, Barda, N, Gilboa, M, Nemet, I, Elkader, BA, Fratty, IS, Jaber, H, Mendelson, E, Alroy-Preis, S, Kreiss, Y, Regev-Yochay, G & Mandelboim, M 2022, 'COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022', Eurosurveillance, vol. 27, no. 30. https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200559

TY - JOUR

T1 - COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022

AU - Kliker, Limor

AU - Zuckerman, Neta

AU - Atari, Nofar

AU - Barda, Noam

AU - Gilboa, Mayan

AU - Nemet, Ital

AU - Elkader, Bayan Abd

AU - Fratty, Ilana S.

AU - Jaber, Hanaa

AU - Mendelson, Ella

AU - Alroy-Preis, Sharon

AU - Kreiss, Yitshak

AU - Regev-Yochay, Gili

AU - Mandelboim, Michal

PY - 2022/7/28

Y1 - 2022/7/28

N2 - This work evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.4 and BA.5) in healthcare workers who had breakthrough BA.1 infection. Omicron breakthrough infection in individuals vaccinated three or four times before infection resulted in increased neutralising antibodies against the WT virus. The fourth vaccine dose did not further improve the neutralising efficiency over the third dose against all Omicron variants, especially BA.4 and BA.5. An Omicron-specific vaccine may be indicated.

AB - This work evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.4 and BA.5) in healthcare workers who had breakthrough BA.1 infection. Omicron breakthrough infection in individuals vaccinated three or four times before infection resulted in increased neutralising antibodies against the WT virus. The fourth vaccine dose did not further improve the neutralising efficiency over the third dose against all Omicron variants, especially BA.4 and BA.5. An Omicron-specific vaccine may be indicated.

UR - https://www.scopus.com/pages/publications/85135420995

U2 - 10.2807/1560-7917.ES.2022.27.30.2200559

DO - 10.2807/1560-7917.ES.2022.27.30.2200559

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35904058

AN - SCOPUS:85135420995

SN - 1025-496X

VL - 27

JO - Eurosurveillance

JF - Eurosurveillance

IS - 30

ER -

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this